Results 211 to 220 of about 75,048 (254)
How glucagon-like is glucagon-like peptide-1? [PDF]
Diabetologia, 1984 Although glucagon-like peptide-1 has the appearance of a glucagon-homologue that may be co-secreted with glucagon, synthetic glucagon-like peptide-1-(1-37) does not significantly affect plasma glucose and insulin concentrations when administered at high doses (100 and 400 micrograms) to cortisone-pretreated rabbits.
M Ghiglione, L O Uttenthal
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Glucagon-like peptide-1 and glucagon-like peptide-2
Best Practice & Research Clinical Endocrinology & Metabolism, 2004The glucagon-like peptides (glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)) are released from enteroendocrine cells in response to nutrient ingestion. GLP-1 enhances glucose-stimulated insulin secretion and inhibits glucagon secretion, gastric emptying and feeding. GLP-1 also has proliferative, neogenic and antiapoptotic effects on
Laurie L. Baggio, Daniel J. Drucker
openaire +1 more source
Glucagon Like Peptide-1 and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry, 2012Patients with type 2 diabetes mellitus are at high risk for developing cardiovascular diseases. Traditional medicines for type 2 diabetes, such as sulfonylureas, pioglitazone, and insulin have glucose lowering effects; however, they also increase the frequency of hypoglycemia and/or body weight and thus may cancel out the benefits of glucose lowering ...
Tomoya, Mita, Hirotaka, Watada
openaire +2 more sources
Metabolic Messengers: glucagon-like peptide 1
Nature Metabolism, 2021Glucagon like peptide-1 (GLP-1), a peptide hormone from the intestinal tract, plays a central role in the coordination of postprandial glucose homeostasis through actions on insulin secretion, food intake and gut motility. GLP-1 forms the basis for a variety of current drugs for the treatment of type 2 diabetes and obesity, as well as new agents ...
Fiona M. Gribble, Frank Reimann
openaire +2 more sources
The Physiology of Glucagon-like Peptide 1
Physiological Reviews, 2007Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the intestinal epithelial endocrine L-cells by differential processing of proglucagon, the gene which is expressed in these cells. The current knowledge regarding regulation of proglucagon gene expression in the gut and in the brain and mechanisms responsible for the ...
openaire +3 more sources
The discovery of glucagon-like peptide 1
Regulatory Peptides, 2005The discovery of glucagon-like peptide 1 (GLP-1) began more than two decades ago with the observations that anglerfish islet proglucagon messenger RNAs (mRNAs) contained coding sequences for two glucagon-related peptides arranged in tandem. Subsequent analyses revealed that mammalian proglucagon mRNAs encoded a precursor containing the sequence of ...
openaire +2 more sources
Glucagon-like peptide-1 agonists
BMJ, 2012Cannot be recommended strictly for weight reduction until their benefits and risks are ...
openaire +2 more sources
Glucagon-like peptide-1 in the pathogenesis of obesity
Drug News & Perspectives, 1998The recently discovered gut peptide glucagon-like peptide-1 (GLP-1) is one of many peptides implicated in the short-term regulation of appetite. GLP-1 is a 30-amino-acid peptide that is produced in and secreted from the L cells of the intestinal mucosa after intake of a mixed meal.
E, Näslund, P M, Hellström
openaire +2 more sources
Glucagon-like peptide 1 in health and disease
Nature Reviews Endocrinology, 2018In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates insulin release and suppresses glucagon secretion in response to the ingestion of nutrients. GLP1 also delays gastric emptying and increases satiety. In patients with type 2 diabetes mellitus (T2DM), supraphysiological doses of GLP1 normalize the endogenous insulin ...
Andreas Andersen +3 more
openaire +3 more sources